THE PLACE OF MIRABEGRON IN CLINICAL PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, a wide range of different drugs is available for te management of overactive bladder. This creates problems when it comes to drug selection and personalized care for each patient. Mirabegron is the only ß3-adrenomimetic agent for the treatment of urinary disorders, which, after careful long-term multi-center randomized trials, has been approved for use in Europe and North America. Mirabegron has proven to be very effective in patients who had previously received anticholinergic drugs and discontinued them because of the insufficient therapeutic effect or pronounced adverse reactions. However, the question of using Mirabegron as a first-line treatment for overactive bladder and the existing limitations in its administration in clinical urology practice remains open.

Full Text

Restricted Access

About the authors

G. R Kasyan

A.I. Evdokimov MSUMD

Email: g.kasyan@outlook.com
Dr.Med.Sci., Prof. at the Department of Urology Moscow, Russia

S. O Sukhikh

A.I. Evdokimov MSUMD

Ph.D. Student at the Department of Urology Moscow, Russia

D. Yu Pushkar

A.I. Evdokimov MSUMD

Corr.-Member of the RAS, Dr.Med.Sci., Prof., Head of the Department of Urology Moscow, Russia

References

  1. Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Am J Obstet Gynecol. 2002;187:116-126.
  2. Wilson L., Brown J.S., Shin G.P. et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398-406.
  3. D’Souza A., Smith M., Miller L., Doyle J., Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14:291-301.
  4. Tomaszewski J. Postmenopausal overactive bladder. Prz Menopauzalny. 2014;13(6):313-329.
  5. Adrian Wagg, Victor W. Nitti, Con Kelleher, David Castro-Diaz, Emad Siddiqui, Todd Berner. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Current Medical Research and Opinion. 2016. doi: 10.1185/03007995.2016.1149806.
  6. Yamaguchi O., Chapple C. b3-Adrenoceptors in urinary bladder. NeurourolUrodyn. 2007;26:752-756.
  7. Kanai A., Wyndaele J., Andersson K., Fry C., Ikeda Y., Zabbarova I. et al. Researching bladder afferents determining the effects of b3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011;30:684-691.
  8. Lindholm P., Lose G. Terbutaline (Bricanyl) in the treatment of female urge incontinence. Urol Int. 1986;41:158-160.
  9. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br J Obstetr Gynaecol. 1984;91:275-278.
  10. Takasu T., Ukai M., Sato S. Matsui T., Nagase I., Maruyama T. et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642-647.
  11. Kasyan G.R. Mirabegron - a New Drug for Treatment of Overactive Bladder. Urologiia. 2015;4:121-124. Russian (Касян Г.Р. Мирабегрон - новый препарат для лечения гиперактивного мочевого пузыря. Урология. 2015;4:121-124).
  12. Chapple C., Wyndaele J., Van Kerrebroeck P., Radziszewski P., Dvorak V., Boerrigter P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol. 2010;(Suppl. 9):249.
  13. Takusagawa S., van Lier J., Suzuki K., Nagata M., Meijer J., Krauwinkel W. et al. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective ß3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40:815-824.
  14. van Gelderen E., Li Q., Meijer J., Schaddelee M., Takusagawa S., Sugawarw T. et al. An explanatory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85(Suppl. 1):abstr. PIII-65.
  15. Khullar V., Cambronero J., Angulo J., Wooning M., Blauwet M., Dorrepaal C. et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post-hoc analysis of a prospective, randomised European - Australian phase III trial. Eur Urol. 2012;11(Suppl.):e684-e684a.
  16. Chapple C., Kaplan S., Mitcheson H., Klecka J., Cummings J., Drogendijk T. et al. Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur Urol. 2012; 11(Suppl.): e683-e683a.
  17. Kaidoh K., Igawa Y., Takeda H., Yamazaki Y., Akahane S., Miyata H. et al. Effects of selective ß2 and ß3-adrenoceptor agonists in detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2012;168:1247-1252.
  18. Hakimi Z., Nazir J., McCrea C., Berling M., Fatoye F., Ramos B., Wagg A. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. J Med Econ. 2017;20(6):614-622. doi: 10.1080/13696998.2017.1294595.
  19. Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.E. Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care. Urologiia. 2016;1:32-39
  20. Aballea S., Maman K., Thokagevistk K. et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015;35:83-93.
  21. Nazir J., Maman K., Neine ME et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Health. 2015;18: 783-790.
  22. Wielage R.C., Perk S., Campbell N.L. et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial healthplan and Medicare Advantage perspectives. J Med Econ. 2016;19:1135- 1143.
  23. Kopp Н. et al. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study. Eur J Obstet Gynecol Reprod Biol.2016; 203:167-172.
  24. Abrams P., Kelleher C., Staskin D., Rechberger T., Kay R., Martina R., Newgreen D., Paireddy A., van Maanen R., Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012.
  25. Drake M.J. et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016. http://dx.doi.org/10.1016/j.eururo.2016.02.030

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies